Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2020

View Archived Issues

CAR-T therapy as powerful salvage approach in patients with R/R AL with TP53 alterations

PPARgamma controls antifibrotic network

Viral infection may be second hit for familial ALS

ZBP1 as a new therapeutic target in multiple myeloma

JNJ-7706621 reverses resistance to CD37-targeted radioimmunotherapy in DLBCL

Celgene presents first-in-human data for CC-90009

Cadila Healthcare divulges new antimycobacterial compounds

Chiesi Farmaceutici identifies ROCK1 and ROCK2 inhibitors

BioTheryX presents new compounds for cancer

Chemrar Research & Development Institute discloses dopamine D2 and D3 receptor agonists

New muscarinic M1 receptor antagonists presented by Pipeline Therapeutics

Durect discontinues development of DUR-928 for psoriasis

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Novel copy number genetic variants identified in Diamond Blackfan anemia

Orphazyme reports new data and analysis supporting arimoclomol in NPC

Phase III GRAVITAS-301 study of itacitinib in treatment-naive GvHD misses primary endpoint

Civi Biopharma studies PCSK9 inhibitor CIVI-007 in phase IIa study

Novan reports topline efficacy data from phase III B-SIMPLE program of SB-206 for molluscum

Glutamine transporter variant identified as new cancer target

Taiwan FDA approves Lumosa's IND for LT-5001 for uremic pruritus

Sol-Gel initiates phase I study of SGT-210 in punctate palmoplantar keratoderma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...